---

Endoxifen and Armodafinil: A Comprehensive Pharmacological Review

---

PART 1: ENDOXIFEN

---

Overview and Classification

1. Selective Estrogen Receptor Modulator (SERM)
2. Protein Kinase C (PKC) inhibitor - this is its primary mechanism in psychiatry

---

Why Endoxifen Instead of Tamoxifen?

---

Mechanism of Action (PKC Hypothesis of Mania)

• PKC is an intracellular serine-threonine kinase that regulates neuronal excitability, neurotransmitter release, and synaptic plasticity
• During manic episodes, PKC activity is thought to be pathologically overactivated in key limbic and prefrontal circuits
• Endoxifen inhibits PKC isozymes (particularly PKC-alpha and PKC-beta) - this is believed to reduce the hyperactivated neuronal firing patterns underlying mania
• Additionally, endoxifen acts as a SERM: it binds estrogen receptors and causes proteasomal degradation of ERalpha, though this SERM activity is not thought to contribute meaningfully to its antimanic effect
• There may also be downstream effects on protein kinase A (PKA) and the glycogen synthase kinase-3 (GSK-3) pathway - similar to lithium's mechanism

---

Pharmacokinetics

---

Pharmacodynamics

• Potent, selective PKC inhibitor (4x more potent than tamoxifen in PKC inhibition assays)
• SERM activity: partial agonist/antagonist at estrogen receptors depending on tissue
• Causes ERalpha proteasomal degradation (relevant to breast cancer but less so in psychiatry)
• No significant receptor activity at dopamine, serotonin, or histamine receptors
• No monoamine reuptake inhibition

---

Approved Indications (Psychiatric)

1. Acute mania associated with bipolar I disorder (India approval)
2. Mixed features (mania with depressive features)
3. Being studied as: adjunct therapy, maintenance treatment (insufficient data currently)

---

Evidence-Based Trials

• 3-week, multicenter trial
• Compared endoxifen 4 mg/day and 8 mg/day vs. divalproex (1000 mg/day as active comparator)
• Primary outcome: reduction in Young Mania Rating Scale (YMRS) scores
• Result: Both doses of endoxifen were non-inferior to divalproex at endpoint; significant reduction in manic and mixed features
• Limitation: Divalproex dose (1000 mg/day) considered sub-therapeutic

• 3-week, multicenter trial
• Endoxifen 8 mg/day vs. divalproex 1000 mg/day
• Confirmed efficacy and safety for acute mania/mixed features
• Significant elevation in lipid profile noted at 3 weeks (most notable safety signal)
• No serious adverse events otherwise

• Included 7 case reports, 2 clinical trials, 1 prospective study
• Conclusion: Short-term efficacy in manic episodes is supported; no serious ADRs except lipid elevation
• Major limitations: Sub-therapeutic comparator dose (divalproex 1000 mg), short duration (21 days), limited data on mixed/depressive episodes and maintenance
• Overall: Evidence is promising but insufficient for broad recommendation - further research needed

• Considered a third-line/adjunct option for acute mania
• Particularly when concurrent impulsivity or aggression is prominent
• Not recommended as monotherapy first-line
• Dose: 8 mg/day

---

Adverse Drug Reactions (ADRs) and Side Effect Profile

• Dyslipidemia - significant elevation in total cholesterol and triglycerides within 3 weeks of treatment (the most clinically concerning finding from trials)

• Hot flashes
• Potential for menstrual irregularities in pre-menopausal women
• Possible effects on bone density with long-term use (extrapolated from tamoxifen data)
• Theoretical risk of endometrial effects (tamoxifen is linked to endometrial cancer - unclear if relevant at psychiatric doses of endoxifen for short-term use)
• DVT/thromboembolic risk (class effect of SERMs - tamoxifen raises DVT risk; long-term endoxifen data lacking)

• Generally well tolerated in trials; no significant neurological ADRs noted

---

Contraindications

• Known hypersensitivity to endoxifen or tamoxifen
• Active thromboembolic disease or high DVT/PE risk (class SERM caution)
• Pregnancy (SERMs are teratogenic)
• Breastfeeding
• Severe hepatic impairment (dose adjustment likely needed; no specific guidance yet)
• Caution with CYP2D6 inhibitors (e.g., SSRIs like fluoxetine, paroxetine) - though less relevant than with tamoxifen since endoxifen is given directly

---

Special Populations

---

Drug Interactions

• CYP3A4 inhibitors/inducers: May alter endoxifen levels (endoxifen is partially metabolized by CYP3A4)
• CYP2D6 inhibitors (SSRIs - paroxetine, fluoxetine): Less relevant for direct endoxifen use; was a major interaction for tamoxifen
• Anticoagulants (warfarin): Monitor INR (SERM class interaction)
• Hormone therapy/OCP: Potential pharmacodynamic antagonism

---

Discontinuation

• No established discontinuation protocol or taper requirement (unlike antidepressants or benzodiazepines)
• Short half-life (2-3 days) means levels clear within ~1-2 weeks
• No documented withdrawal syndrome based on current evidence

---

Precautions

• Baseline and periodic lipid panel monitoring is essential given documented dyslipidemia
• Monitor thromboembolic risk factors before initiating
• Use cautiously in women of reproductive age - ensure adequate contraception
• No long-term safety data beyond 3 weeks of controlled trial evidence

---

---

PART 2: ARMODAFINIL

---

Overview and Classification

• Wakefulness-promoting agent (eugeroic)
• Schedule IV controlled substance (in the US)
• Trade name: Nuvigil (Cephalon/Teva, now distributed by Apotex)

---

Why Armodafinil vs. Modafinil?

• Later Tmax (but sustained higher plasma levels 6-14 hours post-dose)
• Longer effective half-life for the active component
• Higher peak plasma concentrations maintained for longer
• Potentially greater phasic dopamine activation
• Theoretical ability to eliminate need for a second daily dose (often required with modafinil)

---

Mechanism of Action

• Dopamine transporter (DAT) inhibitor - blocks dopamine reuptake, leading to increased synaptic dopamine, particularly in wake-promoting circuits
• Dopamine reuptake inhibitor in nucleus accumbens and striatum

• Activates orexin (hypocretin)-containing neurons in the lateral hypothalamus - these project widely to sleep-regulating brain regions including the locus coeruleus, raphe nuclei, and tuberomammillary nucleus (TMN)
• However, orexin activation is not required for wakefulness promotion (it still works in narcolepsy patients who lack orexin neurons - suggesting this may be secondary)
• Increases extracellular glutamate in medial preoptic area and posterior hypothalamus
• Decreases GABA in these areas
• Acts on catecholamines, serotonin, histamine, and glutamate/GABA systems broadly
• No direct agonism at dopamine receptors (unlike amphetamines)
• No MAO inhibition

---

Pharmacokinetics

---

Pharmacodynamics

• Promotes wakefulness by increasing dopaminergic tone without the "crash" or dysphoria associated with amphetamines
• Lower euphorigenic potential than amphetamines (less mesolimbic dopamine surge)
• Activates histaminergic wake-promoting circuits via downstream orexin activation
• Potential pro-cognitive effects (working memory, executive function, attention) - via noradrenergic and dopaminergic enhancement in prefrontal cortex

---

FDA-Approved Indications

1. Narcolepsy - excessive daytime sleepiness
2. Obstructive Sleep Apnea (OSA)/Hypopnea Syndrome - as an adjunct to standard treatment of the underlying obstruction (e.g., CPAP) to treat residual daytime sleepiness
3. Shift Work Sleep Disorder (SWSD) - taken ~1 hour before shift

---

Off-Label / Investigated Uses in Psychiatry

1. Bipolar depression (adjunctive): A Calabrese et al. (2014) multicenter RCT found significant improvement in MDE associated with Bipolar I disorder with adjunctive armodafinil vs. placebo. However, only 1 of 3 phase 3 studies supported efficacy - evidence is conflicting.
2. Schizophrenia (negative symptoms, cognition, fatigue): Systematic review/meta-analysis showed both modafinil and armodafinil reduced negative symptoms with small effect size; well tolerated. Cognitive effects unclear.
3. Major Depression (fatigue, cognitive symptoms): Mixed evidence; some benefit for fatigue-related symptoms.
4. HIV-related fatigue: RCT (n=70) showed armodafinil significantly reduced HIV-related fatigue; improved depression only when fatigue improved.
5. Multiple Sclerosis fatigue
6. Performance enhancement (off-label, not approved): Used in military, academic, and competitive settings; raises ethical questions.

---

Dosing and Formulations

• Tablets: 50 mg, 150 mg, 200 mg, 250 mg

• Doses up to 250 mg/day are well tolerated in OSA but may not confer additional clinical benefit beyond 150 mg
• Initial dose: 50-150 mg; titrate as needed
• Maximum dose: 250 mg/day

---

Adverse Drug Reactions and Side Effect Profile

• Headache (most common)
• Nausea
• Dizziness
• Insomnia
• Dry mouth
• Anxiety/nervousness

• Diarrhea
• Dyspepsia
• Rhinitis
• Back pain

• Mania/hypomania precipitation
• Psychosis (delusions, hallucinations)
• Suicidal ideation
• Aggression

• Stevens-Johnson Syndrome (SJS) - in pediatric patients: 13/1,585 (0.8%) developed rash leading to discontinuation; 1 case proceeded to SJS. Rashes and SJS have NOT been observed in adults in controlled studies.
• DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) / Multiorgan hypersensitivity reaction - 1 case in pediatric trial
• Angioedema - 1 postmarket case with armodafinil
• Substance abuse/dependence - lower than amphetamines but possible (Schedule IV)

---

Contraindications

• Known hypersensitivity to armodafinil, modafinil, or any formulation ingredient
• No other absolute contraindications

---

Warnings and Precautions

1. Serious rash (SJS/TEN): Discontinue at first sign of rash (unless clearly not drug-related)
2. DRESS: Discontinue if suspected
3. Angioedema/anaphylaxis: Discontinue if suspected
4. Psychiatric symptoms: Use with caution in patients with a history of psychosis, mania, or bipolar disorder; armodafinil can precipitate or worsen these
5. Cardiovascular: Caution in patients with known cardiac disease; may cause palpitations, tachycardia, hypertension
6. Hormonal contraceptives: Armodafinil induces CYP3A4 moderately (more than modafinil) and may reduce the efficacy of hormonal contraceptives - use alternative/additional contraception during treatment and for 1 month after stopping
7. CNS depressants: May be additive when combined with other CNS stimulants

---

Drug Interactions

• Increases levels of: diazepam, phenytoin, propranolol, omeprazole, clomipramine
• In CYP2D6-deficient patients: increases levels of TCAs, SSRIs, bupropion

• Reduces levels of: oral contraceptives (steroids), triazolam, cyclosporine, theophylline
• Clinical action: supplement or switch contraceptive method

• Carbamazepine, phenobarbital, rifampin

• Ketoconazole, erythromycin

---

Special Populations

---

Discontinuation

• No physical dependence in the classical sense (unlike benzodiazepines/opioids)
• No established taper required
• Rebound hypersomnolence may occur briefly on stopping
• As Schedule IV, there is some abuse potential - monitor for psychological dependence in vulnerable patients
• The drug clears relatively quickly (T1/2 ~15 hours), so significant symptoms from abrupt discontinuation are not expected

---

Toxicology / Overdose

• No specific antidote
• Supportive management
• Symptoms of overdose: agitation, insomnia, anxiety, tremor, tachycardia, hypertension
• Hemodialysis not expected to be useful given high protein binding
• In animal models, lethal doses are very high (wide therapeutic index)

---

Key Evidence-Based Trials for Armodafinil

---

Comparative Summary: Endoxifen vs. Armodafinil in Psychiatry

---

• Kaplan & Sadock's Comprehensive Textbook of Psychiatry (9781975175733)
• Stahl's Essential Psychopharmacology (9781108838573)
• The Maudsley Prescribing Guidelines in Psychiatry, 15th ed. (9781394238767)
• Kaplan & Sadock's Synopsis of Psychiatry (9781975145569)
• Bradley and Daroff's Neurology in Clinical Practice (9780323642613)
• Joseph JT et al. Efficacy and safety of endoxifen in bipolar disorder: A systematic review. Hum Psychopharmacol 2024 [PMID 38683854]
• Indian Clinical Practice Guidelines for Bipolar Disorder [PMC12900052]
• FDA Prescribing Information - Nuvigil (armodafinil)
• AASM Practice Guidelines [PMID 34743789]
• Meta-analyses [PMID 39555632; PMID 40388311]